Drug intelligence / Profile preview

TAK-105-b

Development stage: Unknown
Lead developer: Takeda
Modality: Hormonal Peptides → Native Peptides → Peptides
Administration: Subcutaneous

Overview

TAK-105-b is a **peptide agonist** in development by Takeda for the potential treatment of **nausea and vomiting**. It is administered by subcutaneous injection and is a variant/formulation within the TAK-105 program, which includes TAK-105-a as well. The precise molecular target and mechanism of action of TAK-105-b are not publicly disclosed, but it is classified as a peptide/oligonucleotide agonist. The primary indication being studied is nausea and vomiting in healthy adults, with phase I clinical trials focused on safety, tolerability, pharmacokinetics, and maximum tolerated dose. Currently, TAK-105-b has not reached a phase beyond initial human safety studies[1][5][7].

Brand names: TAK-105-bTAK105-bTAK 105-b
Other names: TAK-105-bTAK105-bTAK 105-b

Beyond the preview

Go deeper on TAK-105-b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAK-105-b.

Explore the full profile